Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $76.11 -0.12%
EPS Growth %: +17.5%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
CCEL, MHGU, PLG, More
EPS Growth %: +17.5%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $29.94 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $140-150 million, versus prior guidance of $130-145 million and the consensus of $136.7 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
- Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
- Waller: Recent Increases In Core Inflation Are Quite Broad
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
